All In MedTech

Device Trial Radar · NCT07817147

CREO - Microwave Ablation Feasibility Study

Investigator-Initiated Feasibility Study of a Novel Endoscopic Ultrasound Guided Microwave Ablation Device in Patients With Locally Advanced, Unresectable, or Metastatic Cancer

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Feb 19, 2026

Primary completion

Feb 2028

Study completion Aug 2028

Sponsor

Lead sponsor
Banner HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Creo Medical Limited; CreoMed, Inc.
First posted
Sep 14, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to assess the overall success of energy delivery during treatment using the ultrasound guided microwave ablation device in patients with locally advanced, unresectable, or metastatic cancer. Secondly, this study aims to explore the procedural/clinical safety of treatment with the device and the antitumor effect following treatment with the device.

Conditions

  • Pancreatic Cancer
  • Liver Cancer (Locally Advanced or Metastatic)
  • Pancreatic Cancer Non-resectable
  • Pancreatic Cancer Stage III
  • Pancreatic Cancer Stage IV
  • Liver Cancer Stage IV
  • Liver Cancer Stage IIIa
  • Liver Cancer Stage IIIb
  • Liver Cancer Stage IIIc

Interventions

  • EUS-Guided MWA DeviceDevice

    The rationale of this study is to generate preliminary data on the functionality and safety of Creo's MicroBlate™ Fine device when used under EUS guidance. The results generated from this study will inform any decisions regarding subsequent pivotal trials and may support the integration of this approach into clinical practice for anatomically challenging tumors.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the success of energy delivery during treatment with the deviceTime frame: From first MWA procedure to the end of treatment at Week 5 or 9

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center and Gateway Hospital

    Gilbert, Arizona · Recruiting

  • Cedars Sinai

    Los Angeles, California · Not yet recruiting

  • Rush University Medical Center

    Chicago, Illinois · Not yet recruiting

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.